Related Experiment Videos
Therapies for symptomatic primary osteoporosis
1Department of Endocrinology, Cleveland Clinic Foundation, OH.
Geriatrics
|November 1, 1991
Summary
Currently, no single drug is universally recommended for osteoporosis treatment. However, calcitonin, etidronate disodium, and sodium fluoride show potential, each with unique benefits and drawbacks for bone density and fracture risk.
Area of Science:
- Pharmacology
- Bone Metabolism
- Endocrinology
Background:
- Primary symptomatic osteoporosis lacks a universally accepted pharmacologic treatment.
- Existing treatments offer varying efficacy and side effect profiles.
Purpose of the Study:
- To review promising pharmacologic agents for primary symptomatic osteoporosis.
- To evaluate the efficacy and safety of calcitonin, etidronate disodium, and sodium fluoride.
Main Methods:
- Literature review of studies on calcitonin, etidronate disodium, and sodium fluoride for osteoporosis.
- Analysis of bone density changes, fracture rates, and adverse effects.
Main Results:
- Calcitonin demonstrated increased bone density and analgesic properties.
- Etidronate disodium increased bone density and reduced fractures.
- Sodium fluoride stimulated bone growth but carried risks of toxicity and increased fractures.
Conclusions:
- Calcitonin, etidronate disodium, and sodium fluoride present potential therapeutic options for osteoporosis.
- Each agent requires careful consideration of benefits versus risks, including bone density, fracture reduction, and toxicity.